Sirtuin modulating compounds

Details Sirtuin modulating compounds Sirtuin modulating compounds

2006-08-04

2008-03-18

Saeed, Kamal A. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S366000

Reexamination Certificate

active

07345178

ABSTRACT:
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

REFERENCES:
patent: 4018932 (1977-04-01), Spicer et al.
patent: 2004/0176396 (2004-09-01), Biftu et al.
patent: 2005/0245539 (2005-11-01), Mendla et al.
patent: 1 402 689 (1975-08-01), None
patent: 50-76084 (1975-06-01), None
patent: 52-89689 (1977-07-01), None
patent: 07 291976 (1995-11-01), None
patent: WO-01/27119 (2001-04-01), None
patent: WO-03/007959 (2003-01-01), None
patent: WP-03/11219 (2003-02-01), None
patent: WO-03/028725 (2003-04-01), None
patent: WO-03/028728 (2003-04-01), None
patent: WO-03/042188 (2003-05-01), None
patent: WO-2004/080481 (2004-09-01), None
patent: WO-2005/058884 (2005-06-01), None
patent: WO-2005/069998 (2005-08-01), None
Andreani, et al., “6-(Hydroxyphenyl) Imidazo [2,1-b]Thiazoles as Potential Antiinflammatory Agents: Effects on Human Neutrophil Functions,”Collection of Czechoslovak Chemical Communications, 65:267-279 (2000).
Andreani, et al., “Synthesis and antitubercular activity of imidazol[2,1-b]thiazoles,”European Journal of Medicinal Chemistry, 36:743-746 (2001).
Andreani, et al., “Synthesis and antitumor activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones,”Anti-Cancer Drug Design, 16:167-174 (2001).
Andreani, et al.,“Thienylimidazo[2,1-b]thiazoles as Inhibitors of Mitochondrial NADH Dehydrogenase,”Journal of Medicinal Chemistry, 38:1090-1097 (1995).
Barchechath, et al., “Inhibitors of Apoptosis in Lymphocytes: Synthesis and Biological Evaluation of Compounds Related to Pifithrin-α,”Journal of Medicinal Chemistry, 48:6409-6422 (2005).
Bienayme and Bouzid et al., “A New Heterocyclic Multicomponent Reaction For the Combinatorial Synthesis of Fused 3-Aminoimidazoles,”Angewandte Chemie International Edition, 37(16):2234-2237 (1998).
Forti, et al., “NADPH-generating system: influence on microsomal mono-oxygenase stability during incubation for the liver-microsomal assay with rat and mouse S9 fractions,”Mutation Research, 129:291-297 (1984).
Freymann, et al., Efficient identification of inhibitors targeting the closed active site conformation of the HPRT fromTrypansoma cruzi, Chemistry and Biology, 7:957-968 (2000).
Gemesi, et al., “Application of LC-MS analysis to the characterisation of the in vitro and in vivo metabolite profiles of RGH-1756 in the rat,”Journal of Pharmaceutical and Biomedical Analysis, 24:877-885 (2001).
Hozien, et al., “An Efficient Route for Synthesis of 5,6-Diphenylimidazo-[2,1-b]thiazoles as Antibacterial Agents,”Journal of Heterocyclic Chemistry, 37:943-949 (2000).
Ikeda, et al., “Functional analysis of four naturally occuring variants of human constitutive androslane receptor,”Molecular Genetics and Metabolism, 86:314-319 (2005).
Jinno, et al., “Identification of Novel Alternative Splice Variants of Human Constitutive Androstane Receptor and Characterization of Their Expression in the Liver,”Molecular Pharmacology, 65(3):496-502 (2004).
Laszlovszky, et al., “Substituted phenoxyalkylpiperazines as dopamine D3receptor ligands,”Pharmazie, 56(4):287-289 (2001).
Lewis, et al., “Levamisole-Resistant Mutants of the NematodeCaenorhabditis elegansAppear to Lack Pharmacological Acetylcholine Receptors,”Neuroscience, 5;967-989 (1980).
Terjeki, et al., “An HPLC/UV method for the determination of RGH-1756 in dog and rat plasma,”Journal of Pharmaceutical and Biomedical Analysis, 24:913-920 (2001).
Yagodinets, et al., “Convenient method for the synthesis of phosphorus-containing heterocyclic systems of imidazo[2,1-b]thiazoles, imidazo[2,1-a]pyridines and quinoxalines,”Zhurnal Obshchei Khimii, 54(12):2789-2790 (1984).
Yueh, et al., “High Volume Bioassays to Assess CYP3A4-Mediated Drug Interactions: Induction and Inhibition in a Single Cell Line,”Drug Metabolism and Disposition, 33(1):38-48 (2005).
Porcu, et al., “The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension,” TRENDS in Pharmacological Sciences, 26(2):94-103 (2005).
Database Chemcats Chemical Abstracts Service, Columbus, OH, US; Jan. 18, 2005 (Jan. 18, 2005), XP002384121 ON's STK199474, STK199472, STK199473, STK180355, STK174405, STK196060, STK115373, STK164162, STK136073, STK164152, STK120473, STK052285 -& “Interchim Intermediates” Jan. 18, 2005 (Jan. 18, 2005), Interchim, Montlucon, France, XP002386059.

Affiliated with

Also associated with

Rating

Sirtuin modulating compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sirtuin modulating compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sirtuin modulating compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3962897